CoChat

Inhibition of glioma progression by a newly discovered CD38 inhibitor

Blacher, Eran, Ben Baruch, Bar, Levy, Ayelet, Geva, Nurit, Green, Keith D., Garneau‐Tsodikova, Sylvie, Fridman, Micha, Stein, Reuven · 2015 · International Journal of Cancer
Cited by 69

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Glioma, the most common cancer of the central nervous system, has very poor prognosis and no effective treatment. It has been shown that activated microglia/macrophages in the glioma tumor microenvironment support progression. Hence, inhibition of the supporting effect of these cells may constitute a useful therapeutic approach. Recently, using a syngeneic mouse glioma progression model, we showed that the ectoenzyme CD38 regulated microglia activation and, in addition, that the loss of CD38 from the tumor microenvironment attenuated glioma progression and prolonged the life span of the tumor‐bearing mice. These studies, which employed wild‐type (WT) and Cd38 −/− C57BL/6J mice, suggest that inhibition of CD38 in glioma microenvironment may be used as a new therapeutic approach to treat glioma. Our study tested this hypothesis. Initially, we found that the natural anthranoid, 4,5‐dihydroxyanthraquinone‐2‐carboxylic acid (rhein), and its highly water‐soluble tri‐potassium salt form (K‐rhein) are inhibitors of CD38 enzymatic (nicotinamide adenine dinucleotide glycohydrolase) activity (IC 50 = 1.24 and 0.84 μM, respectively, for recombinant mouse CD38). Treatment of WT, but not Cd38 −/− microglia with rhein and K‐rhein inhibited microglia activation features known to be regulated by CD38 (lipopolysaccharide/IFN‐γ‐induced activation, induced cell death and NO production). Furthermore, nasal administration of K‐rhein into WT, but not Cd38 −/− C57BL/6J, mice intracranially injected with GL261 cells substantially and significantly inhibited glioma progression. Hence, these results serve as a proof of concept, demonstrating that targeting CD38 at the tumor microenvironment by small‐molecule inhibitors of CD38, for example, K‐rhein, may serve as a useful therapeutic approach to treat glioma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.29095

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 69

Metadata

Authors
Blacher, E., Ben Baruch, B., Levy, A., Geva, N., Green, K. D., Garneau‐Tsodikova, S., Fridman, M., & Stein, R.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2014-08-07
Volume
136
Issue
6
Pages
1422-1433
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W1850228883
Cited by
69
References
4
FWCI
1.50
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of glioma progression by a newly discovered CD38 inhibitor. https://app.cochat.ai/papers/10.1002/ijc.29095
The paper
Blacher, E., Ben Baruch, B., Levy, A., Geva, N., Green, K. D., Garneau‐Tsodikova, S., Fridman, M., & Stein, R. (2015). Inhibition of glioma progression by a newly discovered CD38 inhibitor. International Journal of Cancer. https://doi.org/10.1002/ijc.29095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.